Evidence map›Paper›PMID 36121886›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2023

Same-day trial of void and discharge following standard vs. MOSES

Yasser Noureldin, Aurinjoy Gupta, Amr Hodhod, Ahmed S Zakaria, Ruba Abdul Hadi, Vahid Mehrnoush, Loay Abbas, Moustafa Fathy, Amer Alaref, Ahmed Kotb and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Thulium fiber laser versus holmium MOSESProstate cancer and prostatic diseases · 2026
    Trial
  3. Article
  4. Article
  5. Review
  6. Ambulatory surgery for Moses™ holmium laser enucleation of the prostate A prospective, real-practice study from a single center.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Yasser NoureldinDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Aurinjoy GuptaDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Amr HodhodDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ahmed S ZakariaDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ruba Abdul HadiDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Vahid MehrnoushDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Loay AbbasDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Moustafa FathyDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Amer AlarefDepartment of Radiology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ahmed KotbDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Walid ShahrourDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Hazem ElmansyDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
NOSM University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe aimed to compare perioperative and postoperative outcomes and to assess the safety and feasibility of same-day trial of void (TOV) in patients who underwent standard holmium laser enucleation of the prostate (HoLEP) vs. MOSES

methodsWe conducted a retrospective review of prospectively collected data of patients that underwent HoLEP (100 W) or MoLEP (120 W) with same-day catheter removal three hours postoperatively at our institution from August 2018 to September 2021. Patient demographics, intraoperative parameters, and postoperative outcomes were analyzed. Data were compared as means with standard deviation and medians with interquartile range (IQR) or numbers and percentages. Continuous and categorical variables were assessed using the Mann-Whitney U test and Chi-squared test, respectively. Predictors of shorter enucleation time and failed same-day TOV were investigated.

resultsOf the 90 patients included, 28 underwent HoLEP while 62 had MoLEP. There was no significant difference between the groups in terms of the successful TOV (23 [82%] vs. 58 [93.5%], p=0.1) and readmission rate (3 [10.7%] vs. 1 [1.6%], p=0.08); however, the MoLEP group had a significantly shorter mean enucleation time (p<0.001), mean hemostasis time (p<0.001), mean morcellation time (p=0.003), and lower mean energy used (p<0.001). On the logistic regression model, MoLEP (odds ratio [OR] 0.03, 95% confidence interval [CI] 0.007-0.19, p<0.001), lower preoperative prostate-specific antigen (PSA) test (OR 1.25, 95% CI 1.01-1.55, p=0.03), and smaller prostate size (OR 1.06, 95% CI 1.02-1.09, p<0.001) were independent predictors of shorter enucleation time. History of preoperative retention was the only significant factor associated with a failed same-day TOV (p=0.04). There was no difference in intraoperative or postoperative complication rates or postoperative functional outcomes between the two technologies.

conclusionsSame-day TOV and discharge are feasible following standard HoLEP and MoLEP, with comparable outcomes; however, the use of MOSES

Identifiers

PMID36121886
PMCPMC9872824
OpenAlexW4293740501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.